• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • Second Overseas Innovative Medical Device in 2020 Approved via Green Channel

Second Overseas Innovative Medical Device in 2020 Approved via Green Channel

Overseas Innovative Medical Device Fast-Track Approval
Wednesday, 03 June 2020 / Published in Medical Device

Second Overseas Innovative Medical Device in 2020 Approved via Green Channel

On 14.05.2020, the NMPA (National Medical Products Administration) granted the fast-track approval to the global oncology firm Novocure for the registration of Optune, the first tumor-treating fields device to be approved in China to treat glioblastoma.

Optune is only applicable to treat patients, aged 22 or over, with histologically-confirmed glioblastoma multiforme (GBM). Also, it is the first device in China to utilize electric fields for cancer therapy by tuning specific frequencies to disrupt cell division, whilst causing minimal damage to healthy cells.

After the fast-track approval of this new innovative medical device in China, the NMPA will continue to strengthen its measures for post-market surveillance.

On 23.04.2020, the CMDE (Center for Medical Device Evaluation) of NMPA (National Medical Products Administration) announced (No.5-2020) the fast-track approval for Edwards Lifesciences’ transcatheter valve repair clip device, utilizing the special review procedure.

There are three types of fast track channels to encourage innovation and deal with unmet medical needs in China: Innovation Approval, Priority Review, and Emergency Approval. Feel free to request a quotation from us to check if your product qualifies for NMPA registration via a fast track channel.

By Jacky Li. Contact Cisema to learn more.

Tagged under: fast-track approval, Green Channel, innovative medical device

What you can read next

Periodic Risk Evaluation Reports for Medical Device Adverse Events – New Guidelines Issued
Recalls of Medical Device Regulation Updated
Technical Review Guidance Draft for the NMPA Registration of Citric Acid Disinfectants

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • China cosmetics efficacy claims FAQ

    China cosmetics efficacy claims FAQ available to answer key questions

    China cosmetics efficacy claims FAQ is availabl...
  • China cosmetics GMP inspections

    China cosmetics GMP inspections points have been finalised

    China cosmetics GMP inspections points and judg...
  • China medical device quality safety responsibility

    China medical device quality and safety responsibility regulations come into force on March 1, 2023

    China medical device quality and safety respons...
  • China drug standards draft measures

    China drug standards draft measures have been published by the NMPA

    China drug standards draft measures have recent...
  • China special equipment safety supervision

    China special equipment safety supervision – draft provisions released

    China special equipment safety supervision regu...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2021 Cisema. All rights reserved.

TOP
Cookies on Cisema
Learn more about Cisema's Privacy Policy.